An updated narrative review on revolutionizing erectile dysfunction treatment: the crucial role of trophic factors in Adipose-Derived stem cell therapy.
Ghavam A., Sheikhnia F., Heidari MM., Valilo M., Mahmoudnejad Z., Gur S.
Clinical Trial, published in BMC Urol (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- BMC Urol (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40830783
- PMCID
- PMC12362879
- DOI
- 10.1186/s12894-025-01861-0
- Citations
- 1
Abstract (original English)
Erectile dysfunction (ED) is a pervasive condition projected to affect some 322 million men worldwide by 2025, profoundly impairing quality of life and psychosocial well‑being. Current therapies-most notably phosphodiesterase‑5 inhibitors and mechanical devices-offer only transient, symptomatic relief and do not repair the underlying vascular, smooth muscle, and neural degeneration driving ED, particularly in diabetic and neurogenic subtypes. Emerging non‑cellular modalities (e.g. low‑intensity pulsed ultrasound or shockwave therapy) likewise lack demonstrated long‑term safety and durable efficacy. Adipose‑derived stem cell (ADSC) therapy has emerged as a promising regenerative strategy. In preclinical models, ADSCs exert paracrine effects-secreting trophic factors (VEGF, IGF‑1, SDF‑1, NGF) and exosomal microRNAs-that stimulate angiogenesis, smooth muscle restoration, and nerve regeneration. Innovative delivery platforms (thermosensitive hydrogels, size‑controlled spheroids, magnetic guidance) and genetic enhancements (iNOS or PEDF overexpression) further improve cell retention and functional outcomes. Early-phase clinical trials confirm ADSC safety and suggest improvements in International Index of Erectile Function scores, but are limited by small cohorts, heterogeneous protocols, and short follow‑up. Critical gaps persist that hinder translation to routine practice: the long
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.